NRx Pharmaceuticals announced completion of enrollment in its Phase 2b/3 study of NRX-101, the company’s patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. Enrollment of 74 patients exceeded the original target of 70 patients, in order to enhance statistical power of the study. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRXP:
- NRx Pharmaceuticals granted request for transfer of listing to Nasdaq Capital
- NRx Pharmaceuticals receives QIDP, fast track designation from FDA for NRX-101
- NRx Pharmaceuticals announces plan to regain compliance with Nasdaq
- NRx Pharmaceuticals signs agreement with Columbia University
- NRx Pharmaceuticals announces FDA clearance of NRX-101 IND